Open- | Close- |
Vol / Avg.1.000 / 1.698M | Mkt Cap123.819M |
Day Range- - - | 52 Wk Range1.810 - 16.664 |
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.000 / 1.698M | Mkt Cap123.819M |
Day Range- - - | 52 Wk Range1.810 - 16.664 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.220 | ||||||
REV | 237.430M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-11-20 | JP Morgan | Jessica Fye | Reinstates | Underweight | - | - | - |
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -4.02% | 123.8M |
MOLN | Molecular Partners | -1.87% | 138M |
GRPH | Graphite Bio | 0% | 130.5M |
ANIX | Anixa Biosciences | 0.25% | 127.1M |
ADAP | Adaptimmune Therapeutics | -2.4% | 120.8M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Anixa Biosciences (NASDAQ:ANIX), Adaptimmune Therapeutics (NASDAQ:ADAP) and Vistagen Therapeutics (NASDAQ:VTGN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by JP Morgan on Monday, November 20, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $2.39 last updated December 8, 2023 at 9:25 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q4 earnings are confirmed for Monday, February 26, 2024.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.